The effects of a sleep robot intervention on sleep, depression, and anxiety in adults with insomnia

ISRCTN ISRCTN35134834
DOI https://doi.org/10.1186/ISRCTN35134834
Submission date
04/07/2021
Registration date
06/07/2021
Last edited
06/08/2024
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Mental and Behavioural Disorders
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data

Plain English summary of protocol

Background and study aims
Insomnia is a sleep disorder characterized by difficulties initiating sleep, maintaining sleep, and/or early-morning awakenings. Hyperarousal, increased activity of the brain, nervous system, heart rate, and metabolism,​ is thought to be a common cause of insomnia and in maintaining insomnia. Different techniques to decrease arousal have shown to be effective in treating insomnia. Calm breathing can be an approach to enhance sleep. The Somnox sleep robot gives physical and auditive guidance to calm down the users’ breathing. There is currently no impartial empirical evidence of the sleep robot’s effects on insomnia.

Who can participate?
Adults with insomnia

What does the study involve?
Participants will be allocated to one of two groups, with an equal chance of being in either group (like tossing a coin). One group (the active group) will use the sleep robot at home for three weeks, whereas the other group (the control group) will not. Assessments are conducted before, during, and after the treatment for both groups. The control group will receive the intervention after the active phase of the experiment is complete.

What are the possible benefits and risks of participating?
The main benefit of participation is the possibility of symptom relief.

Risks with participation include the individuals’ experiences of invasion of privacy when sensitive questions about psychiatric symptoms and well-being are asked. However, the outcome measures of the current study have been used in many studies without any known complications concerning the character of the questions.

Concerning the risks of infection during the COVID-19 pandemic, the sleep robot has a cover that will be washed between different participants' use of the robots. The screening process is done by phone. Hand sanitizers are provided in physical meetings (e.g. when retrieving the robot). In case of an infected participant, the research group will consult the security manager at Karlstad University, on how to manage the sleep robot. A sleep robot that has been with an infected participant will not be used until an expert explicitly states that it is safe to do so.

Where is the study run from?
Karlstad University (Sweden)

When is the study starting and how long is it expected to run for?
December 2020 to February 2022

Who is funding the study?
Karlstad University (Sweden)

Who is the main contact?
Mrs Siri Jakobsson Støre
siri.store@kau.se

Study website

Contact information

Mrs Siri Jakobsson Støre
Public

Department of Social and Psychological Studies
Karlstad University
Karlstad
SE-651 88
Sweden

ORCiD logoORCID ID 0000-0001-5749-0774
Phone +46547001117
Email siri.store@kau.se

Study information

Study designInterventional randomized waitlist-controlled trial
Primary study designInterventional
Secondary study designRandomised controlled trial
Study setting(s)Home
Study typeTreatment
Participant information sheet Not available in web format, please use contact details to request a participant information sheet.
Scientific titleThe effects of a sleep robot intervention on sleep, depression and anxiety in adults with insomnia - a randomized waitlist-controlled trial
Study objectivesThe intervention group will report significantly greater improvements regarding symptoms of insomnia (total score on the Insomnia Severity Index), compared with the waitlist control group, post-treatment.
Ethics approval(s)Approved 20/01/2021, Swedish Ethical Review Authority (Etikprövningsmyndigheten, Box 2110, 750 02 Uppsala, Sweden; +46104750800; registrator@etikprovning.se), ref: EPM DNR 2020-06975
Health condition(s) or problem(s) studiedInsomnia
InterventionThe active intervention group will use a sleep robot (Somnox) at home for three weeks. Assessments will be conducted at baseline, mid-treatment, and post-treatment for both the active intervention group and the waitlist control group. Participants will be sequentially randomized to one of the two treatment conditions using a 1:1 allocation ratio. The method used to generate the random allocation sequence will be block randomization with a block size of 6. A statistician outside the research group will prepare and record the randomization in advance, and check that the study coordinator abides by the randomization.
Intervention typeDevice
Pharmaceutical study type(s)
PhaseNot Applicable
Drug / device / biological / vaccine name(s)Not provided at time of registration
Primary outcome measureInsomnia measured with the Insomnia Severity Index at baseline, 10, and 24 days
Secondary outcome measures1. Pre-sleep arousal measured with the total score of the Pre-Sleep Arousal Scale at baseline, and 24 days
2. Symptoms of anxiety and depression measured with the total scores from the anxiety and depression scales of the Hospital Anxiety and Depression Scale at baseline, and 24 days
3. Sleep parameters measured with sleep diaries and actigraphy where the values from both will be averaged over a week to compute single summary scores for each of the relevant variables, for the periods -7 to 0 days and 14 to 21 days
Overall study start date01/12/2020
Completion date01/02/2022

Eligibility

Participant type(s)Patient
Age groupAdult
SexBoth
Target number of participants44
Total final enrolment44
Key inclusion criteriaMeets the DSM-5 diagnostic criteria for insomnia disorder as measured by clinical evaluation by a licensed psychologist using the Insomnia severity index (ISI) and the Duke structured clinical interview for sleep disorders (DSISD)
Key exclusion criteria1. Does not speak Swedish
2. Aged <18 years
3. Meet the criteria for another sleep disorder which they are not adequately treated for
4. Meet the diagnostic criteria for a medical or psychiatric condition that may explain the symptoms of insomnia
Date of first enrolment09/08/2021
Date of final enrolment13/12/2021

Locations

Countries of recruitment

  • Sweden

Study participating centre

Karlstad University
Department of Social and Psychological Studies
Karlstad
SE-651 88
Sweden

Sponsor information

Karlstad University
University/education

Department of Social and Psychological Studies
Karlstad
SE-651 88
Sweden

Phone +46547001000
Email info@kau.se
Website http://www.kau.se/
ROR logo "ROR" https://ror.org/05s754026

Funders

Funder type

University/education

Karlstads universitet
Government organisation / Universities (academic only)
Alternative name(s)
Karlstad University, KAU
Location
Sweden

Results and Publications

Intention to publish date01/12/2022
Individual participant data (IPD) Intention to shareYes
IPD sharing plan summaryAvailable on request
Publication and dissemination planPlanned publication in a high-impact peer-reviewed journal
IPD sharing planThe dataset analyzed in the current study will be available upon reasonable request from Siri Jakobsson Støre, siri.store@kau.se, from March 2022 and for 10 years. Informed consent was obtained from the participants, and the data will be anonymized.

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol article 01/11/2021 31/10/2022 Yes No
Results article 25/10/2022 31/10/2022 Yes No
Dataset SPSS file 07/03/2023 No No
Statistical Analysis Plan Section 2.5 01/11/2021 07/03/2023 No No
Results article 13/07/2023 06/08/2024 Yes No

Additional files

ISRCTN35134834 raw data.sav
SPSS file

Editorial Notes

06/08/2024: Publication reference added.
07/03/2023: A datset was uploaded as an additional file.
31/10/2022: The following changes have been made:
1. Publication references added.
2. The final enrolment number has been added from the results reference.
20/08/2021: The following changes were made to the trial record:
1. The recruitment end date was changed from 01/05/2022 to 13/12/2021.
2. The overall trial end date was changed from 01/06/2022 to 01/02/2022.
06/07/2021: Trial’s existence confirmed by Swedish Ethical Review Authority.